Semaglutide cuts heavy drinking 41%

Alcohol-use treatment is a weirdly thin part of medicine. Millions of people need help, but the drug options are basically three old medications that many patients never start or never stay on. That is why this semaglutide result matters. A randomized trial published on April 30 in *The Lancet* says the same GLP-1 drug class behind Ozempic and Wegovy also cut heavy drinking in people with alcohol use disorder and obesity. ### What actually changed? Researchers in Copenhagen enrolled 108 adults who were actively seeking treatment for alcohol use disorder and also had obesity. Everyone got standard cognitive behavioral therapy. Half got weekly semaglutide, titrated up to 2.4 mg, and half got placebo for 26 weeks. This was not a loose observational signal — it was a double-blind randomized trial built to test the question directly. (nih.gov) ### How big was the effect? The headline number is strong. Heavy drinking days dropped 41.1% in the semaglutide group, which was 13.7 percentage points better than placebo. Blood biomarkers lined up with the self-reported drinking data, which matters because alcohol studies always run into the obvious question — did people really drink less, or just say they did? Here, the biomarker data backed the story up. (nih.gov) ### Why is “heavy drinking days” the key measure? Because that is where a lot of the damage sits. Alcohol use disorder is not just about whether someone drank at all. It is about the pattern — the binges, the loss of control, the stretches where risk spikes for injury, liver damage, withdrawal, and relapse. Cutting the heaviest days can change the medical picture even before someone becomes fully abstinent. That is why this endpoint is a real one, not a statistical trick. (nih.gov) ### Why would a weight-loss drug affect alcohol? GLP-1 drugs do more than slow digestion and reduce appetite. They also act on brain circuits tied to reward, craving, and cue response. Basically, the same systems that can make food feel less compelling may also make alcohol less compelling. That idea has been floating around for a while from animal work, registry data, and smaller human studies. This is the first randomized controlled result showing the effect clearly in treatment-seeking patients with both obesity and alcohol use disorder. (thelancet.com) ### Is this better than current AUD drugs? Maybe — but that needs careful wording. The NIH release highlighted an estimated number needed to treat of 4.3 in this trial, versus 7 or higher for approved alcohol-use medications. That sounds impressive, and it is. But cross-trial comparisons are messy — different patients, different endpoints, different settings. The safer takeaway is simpler: semaglutide looks competitive enough that addiction medicine now has to take it seriously. (jamanetwork.com) ### What is the catch? The catch is the population. These were patients with both alcohol use disorder and obesity, treated at a single center, with therapy on top. So this does not prove semaglutide will work the same way in leaner patients, in people not seeking treatment, or in routine primary care. Another recent GLP-1 trial only saw the strongest effect in the obesity subgroup, which is part of why this study focused there. (nih.gov) ### What about side effects and the extra metabolic signals? The expected GLP-1 pattern showed up — more gastrointestinal side effects, but mostly mild and temporary. Researchers also saw bigger improvements in body weight, blood pressure, and other clinical measures in the semaglutide group. That does not prove one unified mechanism, but it does hint that the drug may be changing several linked systems at once — reward, appetite, and cardiometabolic risk. (nih.gov) ### So what is the bottom line? This is not “Ozempic cures alcoholism.” It is narrower and more interesting than that. A serious randomized trial now says semaglutide can reduce heavy drinking in a specific high-risk group that badly needs better options. If larger studies replicate it — and especially if they show the effect beyond people with obesity — GLP-1 drugs could end up reshaping addiction treatment, not just weight loss. (thelancet.com) (nih.gov)